Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kane BiotechKNBIF -22.12% 3-Year FCF Growth Rate is 6.90% as of Mar. 2026, which is 46% below its 10-year median of 12.80. The stock has 6 warning signs investors should review. Among 1,116 Biotechnology companies, Kane Biotech ranks worse than 65.77% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 6.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.60% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 10.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Kane Biotech was 44.40% per year. The lowest was -29.40% per year. And the median was 12.80% per year.
Kane Biotech (OTCPK:KNBIF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Kane Biotech 3-Year FCF Growth Rate Related Terms
KNBIF vs VRTX, REGN, RVMD: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Kane Biotech's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Kane Biotech's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Kane Biotech (KNBIF) has a 3-Year FCF Growth Rate of 6.90% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Kane Biotech and its competitors. This is 46% below median its historical median of 12.80. According to the industry distribution chart, Kane Biotech ranks #734 out of 1116 companies in the Biotechnology industry, placing it in the top 65.8%.
Is Kane Biotech's 3-Year FCF Growth Rate too high?
Kane Biotech's current 3-Year FCF Growth Rate of 6.90% is 46% below median its 10-year median of 12.80. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. Kane Biotech's value of 6.90% is 64.2% below this industry median. Based on the distribution chart, Kane Biotech ranks #734 out of 1116 companies in the Biotechnology industry, which is below the industry midpoint.
How does Kane Biotech's 3-Year FCF Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #734 out of 1116 companies for 3-Year FCF Growth Rate. This places Kane Biotech in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 19.30. Kane Biotech's value of 6.90% is 64.2% below this benchmark. While the company's 10-year median is 12.80 vs. the industry median of 19.30, Kane Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,116 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current 3-Year FCF Growth Rate of 6.90% is 64.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Kane Biotech and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current 3-Year FCF Growth Rate is 6.90%, which is 46% below median its own 10-year median of 12.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current 3-Year FCF Growth Rate of 6.90%. The current 3-Year FCF Growth Rate is 6.90%, which is 46% below median its 10-year median of 12.80 and 64.2% below the Biotechnology industry median of 19.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current 3-Year FCF Growth Rate is 6.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 
